Coronavirus (Covid-19)
A collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.
CORONAVIRUS (COVID-19) VACCINE RESOURCES VACCINE FAQ
-
-
Original Article
NVX-CoV2373 Vaccine Efficacy against B.1.351 in South Africa
V. Shinde and Others
A randomized, phase 2 trial in South Africa compared the NVX-CoV2373 nanoparticle vaccine with placebo in participants with confirmed SARS-CoV-2 infection, including 30% who were seropositive at baseline. Overall vaccine efficacy was 49.4%, with the B.1.351 variant identified in more than 90% of isolates.
May 05Editorial Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control
-
-
-
Correspondence
Efficacy of the BNT162b2 mRNA Vaccine in Qatar
L.J. Abu-Raddad, H. Chemaitelly, and A.A. Butt
As of March 31, 2021, more than 265,000 people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing indicated that 50.0% of infections from February 23 to March 18 were caused by B.1.351 and 44.5% by B.1.1.7. Vaccine effectiveness was 89.5% against the B.1.1.7 variant and 75.0% against the B.1.351 variant. Effectiveness against severe, critical, or fatal disease was 97.4%.
May 05 -
Original Article
Efficacy of the ChAdOx1 Vaccine against the B.1.351 Variant
S.A. Madhi and Others
A double-blind randomized trial in South Africa documented poor efficacy of two doses of the ChAdOx1 nCoV-19 vaccine against the B.1.351 variant of SARS-CoV-2 that emerged in South Africa. Infections occurred in 3.2% of placebo recipients and in 2.5% of vaccine recipients. Thirty-nine of the 42 virus isolates were the B.1.351 variant. None of the cases led to hospitalization or death.
Mar 16
-
Correspondence
Efficacy of the BNT162b2 mRNA Vaccine in Qatar
L.J. Abu-Raddad, H. Chemaitelly, and A.A. Butt
-
-
Original Article
mRNA Covid-19 Vaccine Safety in Pregnant Persons
T.T. Shimabukuro and Others
Preliminary data from the CDC “v-safe after vaccination health checker” surveillance system, the v-safe pregnancy registry, and the Vaccine Adverse Event Reporting System did not show any obvious safety signals among pregnant persons who received mRNA Covid-19 vaccines. More data are needed to better inform maternal, pregnancy, and infant outcomes.
Apr 21
-
-
-
Perspective
Missing the Point
S. Ratzan and Others
To date, relatively few Americans have received Covid vaccinations where they usually receive care: their regular doctor’s office. Going forward, the sidelining of primary care clinicians and health systems that people trust could hinder progress and undermine equity.
May 05 -
Original Article
Brief Report
Variant SARS-CoV-2 Infection after Vaccination
E. Hacisuleyman and Others
Mild Covid-19 symptoms developed in two fully vaccinated persons. Serum tests showed high titers of antibodies capable of neutralizing the wild-type strain of SARS-CoV-2 first identified in Wuhan, China, but sequencing of the virus isolates revealed novel variants. Some mutations in the receptor-binding domain of the spike protein were shared by the two variant strains.
Apr 21
-
Perspective
Missing the Point
S. Ratzan and Others
-
-
Original Article
Ad26.COV2.S Vaccine Efficacy against Covid-19
J. Sadoff and Others
Ad26.COV2.S is a replication-incompetent human adenovirus 26 containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against infection and 85% against severe–critical Covid-19. Efficacy against the variant first identified in South Africa was 64% against moderate disease and 82% against severe–critical disease.
Apr 21 -
Correspondence
Response to Vaccine after Recovery from Covid-19
G. Anichini and Others
The response to the BNT162b2 vaccine was evaluated in 100 health care workers, 38 of whom had recovered from Covid-19. Neutralizing antibody levels were higher 10 days after a single dose in persons who had been previously infected than 10 days after the second dose in those who had not been previously infected.
Apr 14
-
Original Article
Ad26.COV2.S Vaccine Efficacy against Covid-19
J. Sadoff and Others
-
-
Correspondence
Persistence of Antibody after mRNA-1273 Vaccination
N. Doria-Rose and Others
A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months after vaccination. SARS-CoV-2 neutralizing activity was maintained in all the patients through the entire period of follow-up. A half-life of 202 days was determined for the live-virus neutralization activity.
Apr 06
-
-
-
Correspondence
Persistence of Antibody after mRNA-1273 Vaccination
N. Doria-Rose and Others
A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months after vaccination. SARS-CoV-2 neutralizing activity was maintained in all the patients through the entire period of follow-up. A half-life of 202 days was determined for the live-virus neutralization activity.
Apr 06 -
Correspondence
BNT162b2 Efficacy among Israeli Health Care Workers
S. Benenson and Others
A systematic program to vaccinate health care workers at Hadassah Medical Center demonstrated a high level of effective prevention of Covid-19 beginning in the second week after the first of two doses of the BNT162b2 vaccine.
May 06
-
Correspondence
Persistence of Antibody after mRNA-1273 Vaccination
N. Doria-Rose and Others
-
-
Correspondence
Neutralization of SARS-CoV-2 Variants by Convalescent and Vaccinee Serum
G.-L. Wang and Others
Analysis of serum samples from patients convalescing after SARS-CoV-2 infection and after vaccination with BBIBP-CorV or CoronaVac vaccines in China showed neutralizing-antibody titers against the B.1.1.7 strain that were similar to those against the wild-type (Wuhan) strain but were variably lower against the B.1.351 strain.
Apr 06 -
Correspondence
SARS-CoV-2 Vaccine and Infection in Health Workers
J. Keehner and Others
After more than 36,500 health care workers at the University of California received at least one dose of vaccine, 71% of 379 workers with positive SARS-CoV-2 tests had positive results within 2 weeks after the first dose. Of 37 workers with positive results after the second dose, 7 had positive results 15 or more days after the dose.
May 06
-
Correspondence
Neutralization of SARS-CoV-2 Variants by Convalescent and Vaccinee Serum
G.-L. Wang and Others
-
-
Original Article
Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
M. Scully and Others
Scully and colleagues report 23 cases of abnormal clotting, primarily involving the cerebral veins, 6 to 24 days after the first dose of the ChAdOx1 nCoV-19 vaccine. The syndrome was incited by antibodies to platelet factor 4, independent of heparin therapy. Early recognition and avoidance of platelet transfusion are key.
Apr 16Editorial SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
-
-
-
Correspondence
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Manufacturer’s Response
J. Sadoff, K. Davis, and M. Douoguih
The manufacturer of the Ad26.COV2.S vaccine against Covid-19 comments on recent reports of thrombosis, including cerebral venous sinus thrombosis, associated with severe thrombocytopenia in several recipients of the vaccine.
Apr 16 -
Correspondence
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccine
K.-L. Muir and Others
A 48-year-old woman presented with a 3-day history of fatigue and abdominal pain 2 weeks after receiving the Ad26.COV2.S vaccine. She had a low platelet count and was found to have cerebral venous sinus thrombosis and clots in the right hepatic and splenic veins. Testing for antibody to PF4–polyanion was positive.
Apr 14
-
Correspondence
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Manufacturer’s Response
J. Sadoff, K. Davis, and M. Douoguih
-
-
Original Article
Thrombosis after ChAdOx1 nCoV Vaccination
A. Greinacher and Others
In this case series, investigators report a very rare but life-threatening sequela of ChAdOx1 nCoV vaccination. Beginning 5 to 16 days after a first injection, some patients had symptoms consistent with thrombocytopenia, disseminated intravascular coagulation, and thromboses, including cerebral venous sinus thrombosis with catastrophic outcome. An anti–PF4 antibody capable of platelet activation appears to be the cause. Intravenous immune globulin may be therapeutic.
Apr 09
-
Original Article
Thrombosis after ChAdOx1 nCoV Vaccination
A. Greinacher and Others
-
-
Original Article
Brief Report
ChAdOx1 nCoV-19 and Immune Thrombotic Thrombocytopenia
N.H. Schultz and Others
This report describes a very rare but life-threatening sequela of vaccination with ChAdOx1 nCoV-19. Within 10 days after a first injection, five health care workers presented with thrombocytopenia and thromboses, including cerebral venous sinus thrombosis with catastrophic outcome. The apparent cause is an anti-PF4 antibody capable of platelet activation; intravenous immune globulin may be therapeutic.
Apr 09
-
Original Article
Brief Report
ChAdOx1 nCoV-19 and Immune Thrombotic Thrombocytopenia
N.H. Schultz and Others
-
-
Original Article
Antibodies and SARS-CoV-2 Infection in Health Workers
S.F. Lumley and Others
In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.
Dec 23
-
-
-
Correspondence
Cross-Reactive Antibody Responses Elicited by the 501Y.V2 Variant
T. Moyo-Gwete and Others
Convalescent serum from persons who had recovered from infection with 501Y.V2 (B.1.351), a SARS-CoV-2 variant first identified in South Africa, showed potent neutralization of the original variant (D614G), the 501Y.V2 variant, and the P.1 variant first identified in Brazil. These results suggest that vaccines based on the 501Y.V2 spike protein may be broadly effective against two common variants of SARS-CoV-2.
Apr 07 -
Correspondence
Duration of Positive SARS-CoV-2 on RT-PCR and Culture
M.-C. Kim and Others
In 21 consecutive patients with confirmed Covid-19, the median times from symptom onset to negative viral culture and negative real-time RT-PCR were 7 days and 34 days, respectively. The longest interval from symptom onset and from resolution of fever to positive culture was 12 days and 3 days, respectively.
Feb 18Correspondence Viable SARS-CoV-2 Shedding
See Also Chinese Translation in NEJM 医学前沿
-
Correspondence
Cross-Reactive Antibody Responses Elicited by the 501Y.V2 Variant
T. Moyo-Gwete and Others
-
-
Correspondence
Shedding of SARS-CoV-2 after Immunosuppression
T. Aydillo and Others
The prolonged contagious period after viral infection in immunocompromised patients may affect how long precautions will be necessary to reduce further transmission. Replication-competent SARS-CoV-2 was detected for up to 61 days in patients who were immunocompromised by treatment for cancer.
Dec 24
-
Correspondence
Shedding of SARS-CoV-2 after Immunosuppression
T. Aydillo and Others
-
-
Original Article
Durable Humoral Response to SARS-CoV-2
D.F. Gudbjartsson and Others
This large comparative study of the Icelandic population showed that the humoral response did not decline within 4 months after infection, that 44% of persons who had been infected had not been diagnosed with qPCR, and that the infection fatality risk was 0.3%.
Oct 29Editorial The Power of Antibody-Based Surveillance
-
Original Article
Durable Humoral Response to SARS-CoV-2
D.F. Gudbjartsson and Others
-
-
Original Article
Passive Immunotherapy in Patients with Covid-19
M.J. Joyner and Others
Among more than 3000 hospitalized patients with Covid-19, recipients of high-titer convalescent plasma had a lower mortality at 30 days than recipients of low-titer plasma. The effect of high-titer plasma was greatest in the subgroup of patients who were not receiving mechanical ventilation.
Jan 13Editorial (A Little) Clarity on Convalescent Plasma for Covid-19
-
-
-
Clinical Implications of Basic Research
Fighting SARS-CoV-2 with Nanobodies
R. Sasisekharan
New therapies effective against the SARS-CoV-2 virus are desirable. Could nanobodies represent an arrow in the quiver of therapeutic strategies to treat Covid-19?
Apr 07 -
Original Article
Convalescent Plasma in Early Covid-19 Infection
R. Libster and Others
High-titer convalescent plasma was compared with placebo in older adult patients within the first 3 days after the onset of symptoms of Covid-19 and documented SARS-CoV-2 infection. Disease progression was approximately half as common in patients who received convalescent plasma (16%) as in those who received placebo (31%).
Feb 18Editorial (A Little) Clarity on Convalescent Plasma for Covid-19
-
Clinical Implications of Basic Research
Fighting SARS-CoV-2 with Nanobodies
R. Sasisekharan
-
-
Original Article
Interleukin-6 Receptor Blockade in Severe Covid-19
The REMAP-CAP Investigators
The interleukin-6 receptor blockers tocilizumab and sarilumab were tested against standard care in a randomized trial involving patients newly admitted to the intensive care unit and requiring respiratory or blood-pressure support. The median number of organ support–free days was 10 with tocilizumab, 11 with sarilumab, and 0 with standard care.
Feb 25Editorial Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
-
Original Article
Interleukin-6 Receptor Blockade in Severe Covid-19
The REMAP-CAP Investigators
-
-
Original Article
Tocilizumab in Severe Covid-19 Pneumonia
I.O. Rosas and Others
In this randomized trial involving 438 hospitalized patients with severe Covid-19 pneumonia, the use of the monoclonal antibody tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.
Feb 25
-
Original Article
Tocilizumab in Severe Covid-19 Pneumonia
I.O. Rosas and Others
-
-
Original Article
Dexamethasone Treatment in Covid-19
The RECOVERY Collaborative Group
Among hospitalized patients with Covid-19, treatment with dexamethasone resulted in lower 28-day mortality than usual care, according to the level of respiratory support the patients were receiving, indicating a possible correlation between efficacy and the stage of infection.
Feb 25Editorial Research in the Context of a Pandemic
Editorial The RECOVERY Platform -
Original Article
Neutralizing-Antibody Therapy in Covid-19
P. Chen and Others
In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%).
Jan 21Editorial Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
Original Article REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Correspondence Neutralizing Antibody LY-CoV555 for Outpatient Covid-19
-
Original Article
Dexamethasone Treatment in Covid-19
The RECOVERY Collaborative Group
-
-
Original Article
LY-CoV555 in Hospitalized Patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group
In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.
Mar 11Correspondence Monoclonal Antibody for Patients with Covid-19
-
Original Article
Antibody Cocktail in Early SARS-CoV-2 Infection
D.M. Weinreich and Others
An anti–SARS-CoV-2 antibody cocktail was given to patients within 3 days after PCR confirmation of Covid-19. In patients who were antibody-negative at baseline, treatment was associated with rapid viral clearance and potentially with a less frequent need for medical attention. The effect was less marked among patients who were antibody-positive at baseline.
Jan 21Original Article SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Editorial Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
-
Original Article
LY-CoV555 in Hospitalized Patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group
-
-
Clinical Practice
Mild or Moderate Covid-19
R.T. Gandhi, J.B. Lynch, and C. del Rio
The diagnosis of Covid-19 is usually based on SARS-CoV-2 PCR testing of a nasopharyngeal swab or other specimen. Remdesivir and dexamethasone have benefits in hospitalized patients with severe Covid-19, but in patients with moderate disease, dexamethasone is not efficacious and data are insufficient to recommend for or against routine use of remdesivir.
Oct 29
-
-
-
Perspective
Health Care Worker Strikes and the Covid Pandemic
R. Essex and S.M. Weldon
Covid-19 appears to have led to a substantial uptick in strike actions by health care workers, protesting inadequate pandemic responses and protections. Such strikes raise questions about what health care workers owe society and what society owes them.
Apr 07 -
Clinical Practice
Severe Covid-19
D.A. Berlin, R.M. Gulick, and F.J. Martinez
Patients with severe Covid-19 should be closely monitored regarding the need for endotracheal intubation; intubated patients should receive lung-protective ventilation. Data from randomized, controlled trials are awaited to inform the use of antiviral and immunomodulatory therapies; preliminary data support benefits of remdesivir in this population.
May 15See Also Chinese Translation in NEJM 医学前沿
-
Perspective
Health Care Worker Strikes and the Covid Pandemic
R. Essex and S.M. Weldon
-
-
Videos in Clinical Medicine
Emergency Intubation in Covid-19
G.S. Shrestha and Others
This video demonstrates the procedure for emergency endotracheal intubation in patients with suspected or proven Covid-19. Endotracheal intubation in such patients poses a risk of infection for the health care personnel involved. Meticulous planning and preparation and the use of practice drills can minimize this risk.
Feb 18Letters responding to this article are now published: Emergency Intubation in Covid-19
-
-
-
Videos in Clinical Medicine
Percutaneous Tracheostomy
D.A. Hashimoto, A.L. Axtell, and H.G. Auchincloss
A tracheostomy is a surgically created airway that is kept open with a breathing tube, or tracheostomy tube. This video demonstrates percutaneous tracheostomy, a procedure that may be performed at the patient’s bedside, including patients with Covid-19, who may require a tracheostomy in the course of severe respiratory distress.
Oct 28Correspondence Percutaneous Tracheostomy
-
Videos in Clinical Medicine
Family Meetings on Behalf of Patients with Serious Illness
E. Widera and Others
Effective family meetings build rapport and offer support, provide updates about a patient’s medical status and prognosis, and ensure treatment that is consistent with the patient’s goals. Such meetings can result in better use of health care resources. This video demonstrates how to have an effective family meeting.
Sep 10
-
Videos in Clinical Medicine
Percutaneous Tracheostomy
D.A. Hashimoto, A.L. Axtell, and H.G. Auchincloss
-
-
Correspondence
Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden
Ludvigsson et al. reported on open schools and child and teacher morbidity in Sweden during the Covid-19 pandemic. The authors of two letters further the discussion and Ludvigsson et al. respond.
Mar 01Correspondence Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden
-
Medicine and Society
Reopening Primary Schools during the Pandemic
M. Levinson, M. Cevik, and M. Lipsitch
It would be best — and evidence from many countries demonstrates that it’s possible — to lower community transmission rates by means of stringent control measures this summer so that schools can reopen this fall with an acceptable level of safety.
Sep 03
-
Correspondence
Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden
-
-
Original Article
Multisystem Inflammatory Syndrome in U.S. Children
L.R. Feldstein and Others
This report describes the epidemiology and clinical course of patients younger than 21 years of age from 26 states who had multisystem inflammatory syndrome. Many were infected with SARS-CoV-2 at least 1 to 2 weeks before syndrome onset. The median age of the patients was 8.3 years, and 73% were previously healthy.
Jul 23Editorial Childhood Multisystem Inflammatory Syndrome — A New Challenge in the Pandemic
Original Article Multisystem Inflammatory Syndrome in Children in New York State
Correspondence Multisystem Inflammatory Syndrome in Children in the United States
See Also Chinese Translation in NEJM 医学前沿
-
-
-
Perspective
SARS-CoV-2 Testing and School Reopening
Y. Rafiei and M.M. Mello
Most U.S. school reopening plans focus on screening for Covid-19 symptoms. But because an estimated 40% of Covid-19 cases are asymptomatic and 50% of transmissions occur from asymptomatic persons, screening testing is critical.
Dec 03 -
Correspondence
Detection of SARS-CoV-2 with a CRISPR-Based Test
J. Joung and Others
A new method for the detection of SARS-CoV-2 combines simplified extraction of RNA with isothermal amplification and CRISPR (clustered regularly interspaced short palindromic repeats)–mediated detection. Testing of 402 samples indicated a sensitivity of 93.1% and a specificity of 98.5%.
Oct 08
-
Perspective
SARS-CoV-2 Testing and School Reopening
Y. Rafiei and M.M. Mello
-
-
Videos in Clinical Medicine
How to Obtain a Nasopharyngeal Swab Specimen
F.M. Marty, K. Chen, and K.A. Verrill
Collecting specimens from the surface of the respiratory mucosa with nasopharyngeal swabs is a procedure used to diagnose Covid-19 as well as other respiratory viral infections and certain bacterial infections in adults and children. This video describes the collection of specimens for detection of Covid-19.
May 28Correspondence How to Obtain a Nasopharyngeal Swab SpecimenSee Also Chinese Translation in NEJM 医学前沿
-
-
-
Correspondence
Patient-Collected Swabs for SARS-CoV-2 Testing
Y.-P. Tu and Others
Tongue, nasal, and mid-turbinate swabs to detect SARS-CoV-2 were collected by 530 outpatients before a health care worker collected nasopharyngeal swabs from these patients. Both the mid-turbinate and the nasal samples collected by the patients themselves may be clinically acceptable, with estimated sensitivities above 90%.
Jul 30
-
Correspondence
Patient-Collected Swabs for SARS-CoV-2 Testing
Y.-P. Tu and Others
-
-
Correspondence
Saliva Specimens to Detect SARS-CoV-2 Infection
A.L. Wyllie and Others
In this letter, the investigators report that saliva specimens and nasopharyngeal swab specimens had similar sensitivity in the detection of SARS-CoV-2 RNA in both symptomatic and asymptomatic persons.
Sep 24Correspondence Saliva for Detection of SARS-CoV-2
-
Correspondence
Saliva Specimens to Detect SARS-CoV-2 Infection
A.L. Wyllie and Others
-
-
Correspondence
Microvascular Changes in the Brain in Covid-19
M.-H. Lee and Others
High-resolution MRI and histopathological study of the brains of patients who had died from Covid-19 showed punctate hyperintensities and punctate or linear hypointensities, which represented various forms of pauci-inflammatory microvasculopathy. No evidence of active viral infection was found.
Dec 30 -
Original Article
Nimble GWAS on Covid-19
The Severe Covid-19 GWAS Group
During the peak of hospitalizations of patients with severe Covid-19 in Italy and Spain in March, a group of researchers in these and other countries obtained and analyzed samples, resulting in the identification of two chromosomal loci associated with the disorder.
Oct 15Editorial Genetic Risk of Severe Covid-19
Correspondence Mining a GWAS of Severe Covid-19See Also Chinese Translation in NEJM 医学前沿
-
Correspondence
Microvascular Changes in the Brain in Covid-19
M.-H. Lee and Others
-
-
Review Article
Cytokine Storm
D.C. Fajgenbaum and C.H. June
Cytokine storm, a life-threatening disorder involving cytokine elevations and immune-cell hyperactivation, has various causes and is characterized by constitutional symptoms, systemic inflammation, and multiorgan dysfunction. Selective interventions can ameliorate the illness.
Dec 03See Also Chinese Translation in NEJM 医学前沿
-
-
-
Original Article
Baricitinib plus Remdesivir for Adults with Covid-19
A.C. Kalil and Others
In a trial involving 1033 patients hospitalized with Covid-19, the addition of baricitinib to remdesivir was associated with shorter recovery time, particularly among patients receiving high-flow oxygen, and with a 30% higher odds of improvement at day 15 than remdesivir alone. Adverse events were less frequent with the combination therapy.
Dec 11
-
-
-
Original Article
Repurposed Antiviral Drugs for Covid-19
WHO Solidarity Trial Consortium
The authors report interim results of the WHO Solidarity trial of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with Covid-19. Effects on overall mortality, initiation of ventilation, and duration of hospital stay are compared.
Dec 02Editorial A Large, Simple Trial Leading to Complex Questions
Perspective FDA Approval of Remdesivir — A Step in the Right Direction -
Original Article
Remdesivir for Covid-19 — Final Report
J.H. Beigel and Others
In this randomized, double-blind trial in 1062 adults hospitalized with Covid-19, remdesivir was superior to placebo in shortening the time to recovery (10 days, vs. 15 days with placebo). The estimates of mortality by day 29 were 11.4% with remdesivir and 15.2% with placebo. The benefit of remdesivir was most apparent in patients who were receiving low-flow oxygen at baseline.
Nov 05Correspondence Remdesivir for the Treatment of Covid-19 — Preliminary Report
See Also Chinese Translation in NEJM 医学前沿
-
Original Article
Repurposed Antiviral Drugs for Covid-19
WHO Solidarity Trial Consortium
-
-
Original Article
Remdesivir for 5 Days or 10 Days in Covid-19
J.D. Goldman and Others
A randomized trial comparing a 5-day course of intravenous remdesivir with a 10-day course in patients with Covid-19 pneumonia and hypoxemia who were not yet receiving mechanical ventilation showed no significant differences in outcome related to the duration of treatment.
Nov 05Editorial Remdesivir — An Important First Step
-
Original Article
Remdesivir for 5 Days or 10 Days in Covid-19
J.D. Goldman and Others
-
-
Original Article
Compassionate-Use Remdesivir for Severe Covid-19
J. Grein and Others
A cohort of patients with severe Covid-19 received treatment with remdesivir under a compassionate-use protocol. Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 18 days.
Jun 11See Also Chinese Translation in NEJM 医学前沿
-
Original Article
Compassionate-Use Remdesivir for Severe Covid-19
J. Grein and Others
-
-
Case Records of the Massachusetts General Hospital
A Man with Headache and Covid-19
H.M. Heller and Others
A 24-year-old man was admitted to the hospital with a 3-week history of headache and a positive test for SARS-CoV-2 RNA. MRI showed multiple small hyperintense foci in the caudate nuclei and putamina. On lumbar puncture, the opening pressure was higher than 55 cm of water; the CSF white-cell count was 108 per microliter. What is the diagnosis?
Dec 24 -
Correspondence
SARS-CoV-2 in an Immunocompromised Host
B. Choi and Others
This letter describes an immunocompromised patient who had persistent infection with SARS-CoV-2 over a period of months, despite several courses of remdesivir. Phylogenetic analysis showed accelerated viral evolution.
Nov 11
-
Case Records of the Massachusetts General Hospital
A Man with Headache and Covid-19
H.M. Heller and Others
-
-
Case Records of the Massachusetts General Hospital
A Woman with Chest Pain, Dyspnea, and Shock
C. Newton-Cheh and Others
A 44-year-old woman presented with cough, dyspnea, and chest pain. On examination, she had tachycardia and hypotension. Evaluation revealed SARS-CoV-2 RNA in a nasopharyngeal swab, as well as elevated levels of troponin and lactic acid and a decline in urine output. Urgent management decisions were made.
Jul 30
-
-
-
Correspondence
Type I Interferonopathy in Muscle in a Man with Covid-19
G.S. Manzano, J.K. Woods, and A.A. Amato
Generalized, predominantly proximal weakness and a greatly elevated creatine kinase level developed in a man with Covid-19. Immunohistochemical analysis of a muscle-biopsy specimen revealed abnormal expression of MHC-1 and myxovirus resistance protein A on muscle fibers, suggesting type I interferonopathy.
Dec 10
-
Correspondence
Type I Interferonopathy in Muscle in a Man with Covid-19
G.S. Manzano, J.K. Woods, and A.A. Amato
-
-
Case Records of the Massachusetts General Hospital
A Woman Who Died from Covid-19
J.R. Stone and Others
A 76-year-old woman was admitted to the hospital with confusion and hypoxemia. Multiple residents at her assisted-living facility had received a diagnosis of Covid-19. Testing of a nasopharyngeal swab was positive for SARS-CoV-2. On the fourth hospital day, respiratory distress developed; 36 hours later, the patient died. An autopsy was performed.
Jul 23
-
Case Records of the Massachusetts General Hospital
A Woman Who Died from Covid-19
J.R. Stone and Others
-
-
Medicine and Society
Tribal Truce
L. Rosenbaum
Since human behavior — including wearing or shunning masks — will determine the ultimate toll of the Covid-19 pandemic, communication strategies that bridge our partisan divide over science may prove as important as any novel therapeutic.
Sep 23 -
Perspective
Facial Masking for Covid-19
M. Gandhi and G.W. Rutherford
Increasing the proportion of SARS-CoV-2 infections that are asymptomatic with the simple public health measure of universal masking might help make the infection less deadly and increase population-level immunity without severe illnesses and deaths.
Sep 08Correspondence Facial Masking for Covid-19
-
Medicine and Society
Tribal Truce
L. Rosenbaum
-
-
Videos in Clinical Medicine
Personal Protective Equipment and Covid-19
R. Ortega and Others
This video demonstrates a procedure for donning and doffing one type of PPE recommended by the CDC for use in hospitals to minimize the risk of exposure to infectious material during the care of patients with Covid-19.
Jun 25Correspondence Personal Protective Equipment and Covid-19
-
-
-
Correspondence
Universal Masking in the Covid-19 Era
M. Klompas, C.A. Morris, and E.S. Shenoy
Klompas and colleagues write that they understand that some people are citing their Perspective article (published on April 1) as support for discrediting widespread masking. In truth, the intent of their article was to push for more masking, not less.
Jul 09Perspective Universal Masking in Hospitals in the Covid-19 Era
-
Correspondence
Universal Masking in the Covid-19 Era
M. Klompas, C.A. Morris, and E.S. Shenoy
-
-
Sounding Board
Allocating Scarce Medical Resources for Covid-19
E.J. Emanuel and Others
The Covid-19 pandemic has already stressed health care systems throughout the world, requiring rationing of medical equipment and care. The authors discuss the ethical values relevant to health care rationing and provide six recommendations to guide fair allocation of scarce medical resources during the pandemic.
May 21Perspective The Toughest Triage — Allocating Ventilators in a Pandemic
Correspondence Allocating Medical Resources in the Time of Covid-19
-
Sounding Board
Allocating Scarce Medical Resources for Covid-19
E.J. Emanuel and Others

